211 related articles for article (PubMed ID: 20566765)
1. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
Sarfo FS; Phillips R; Asiedu K; Ampadu E; Bobi N; Adentwe E; Lartey A; Tetteh I; Wansbrough-Jones M
Antimicrob Agents Chemother; 2010 Sep; 54(9):3678-85. PubMed ID: 20566765
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
Tanywe A; Fernandez RS
JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
[TBL] [Abstract][Full Text] [Related]
3. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
[TBL] [Abstract][Full Text] [Related]
4. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
[TBL] [Abstract][Full Text] [Related]
6. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F
PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
[TBL] [Abstract][Full Text] [Related]
8. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
[TBL] [Abstract][Full Text] [Related]
9. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS;
Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422
[TBL] [Abstract][Full Text] [Related]
10. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Yotsu RR; Richardson M; Ishii N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
12. Buruli ulcer disease in Republic of the Congo.
Marion E; Obvala D; Babonneau J; Kempf M; Asiedu KB; Marsollier L
Emerg Infect Dis; 2014 Jun; 20(6):1070-2. PubMed ID: 24857328
[No Abstract] [Full Text] [Related]
13. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
Adu EJ; Ampadu E
Int J Mycobacteriol; 2015 Jun; 4(2):138-42. PubMed ID: 26972882
[TBL] [Abstract][Full Text] [Related]
15. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
Guarner J
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
Iddrisah FN; Yeboah-Manu D; Nortey PA; Nyarko KM; Anim J; Antara SN; Kenu E; Wurapa F; Afari EA
Pan Afr Med J; 2016; 25(Suppl 1):13. PubMed ID: 28149438
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.
Sarfo FS; Phillips RO; Ampadu E; Sarpong F; Adentwe E; Wansbrough-Jones M
Clin Vaccine Immunol; 2009 Jan; 16(1):61-5. PubMed ID: 19005025
[TBL] [Abstract][Full Text] [Related]
19. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
[TBL] [Abstract][Full Text] [Related]
20. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
